­
­
­
­

Inventi Impact: Animal Models & Cell Assays

Articles

  • Inventi:pac/14523/14
    Antiangiogenesis Therapy of Endometriosis Using PAMAM as a Gene Vector in a Noninvasive Animal\nModel
    01-Jan-1970 Research 2014 : October - December
    Ningning Wang, Bin Liu, Lili Liang, Yanxin Wu, Hongzhe Xie, Jiaming Huang, Xu Guo, Jinfeng Tan, Xuejun Zhan, Yongdong Liu, Liantang Wang, Peiqi Ke

    Objective. To evaluate the characteristics and antiangiogenic effects of endostatin-loaded PAMAM on endometriosis in a\nnoninvasive animal model. Materials and Methods. A noninvasive animal model was established by injecting adenovirus-GFP\ntransfected endometrial stromal and glandular epithelial cells subcutaneously into nude mice. Endostatin-loaded PAMAM was\nprepared and identified by transmission electron microscopy. For in vitro studies, the DNA protection and cytotoxicity of PAMAM\nwere investigated and compared with Lipofectamine 2000. For in vivo study, endostatin-loaded PAMAM was injected into the\nnoninvasive model and evaluated by continuously observing the fluorescent lesion, lesion weight, microvessel density and VEGF\nimmunostaining. Results. Compared with Lipofectamine 2000, PAMAM and HC PAMAM-ES group,MC PAMAM-ES group and\nLC PAMAM-ES group demonstrated a better stromal cells protective such thatMC PAMAM-ES group of CCK8 was 0.617�± 0.122 at\n24 hr and 0.668 �± 0.143 at 48 hr and LC PAMAM-ES group of CCK8 was 0.499 �± 0.103 at 24 hr and 0.610 �± 0.080 at 48 hr in stromal\ncells (P < 0.05) but similar cytotoxicity in glandular epithelial cells in vitro. After 16 hrs of digestion, DNA decreased slightly\nunder the protection of PAMAM. Endostatin-loaded PAMAM of HD PAMAM-ES group and LD PAMAM-ES group inhibited the\ngrowth of the endometriotic lesion in vivo at days 15, 20, 25 and 30 detected by noninvasive observation after injecting one dose\nendostatin of various medicines into the endometrial lesion in each mouse on day 10 (P < 0.05) and confirmed by lesion weight\nat day 30 with HD PAMAM-ES group being 0.0104 �± 0.0077 g and LD PAMAM-ES group being 0.0140 �± 0.0097 g (P < 0.05).\nImmunohistochemistry results showed that endostatin-loaded PAMAMreduced the microvessel density 3.8 �± 2.4 especially in HD\nPAMAM-ES group in the lesion (P < 0.05). Conclusion. Endostatin-loaded PAMAM inhibits the development of endometriosis\nthrough an antiangiogenic mechanism and can be observed through the noninvasive endometriosis model.

    How to Cite this Article
    CC Compliant Citation: Ningning Wang, Bin Liu, Lili Liang, et al., â??Antiangiogenesis Therapy of Endometriosis Using PAMAM as a Gene Vector in a Noninvasive Animal Model,â? BioMed Research International, vol. 2014, Article ID 546479, 11 pages, 2014.\ndoi:10.1155/2014/546479.Copyright © 2014 NingningWang et al. This article is distributed under the Creative CommonsAttribution License,(http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    Download Full Text